-
Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It
Originally Published on Benzinga Technical advancements in stem cell therapies have reportedly shifted the outlook of regenerative medicine, and some scientists are getting increasingly excited. Cardiologist Dr. Joshua Hare is one of those scientists, and he’s both the co-founder and chief scientific officer of Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. He’s also credited with helping to pioneer the use of stem cells as medicine for the human heart and regularly explores a future where regenerative medicine can prolong human life. The global regenerative medicine market is estimated to reach $6.49 billion in 2027, up 9.3% from $3.05 billion in 2019. …
-
Groundbreaking Studies to Be Conducted on the Effectiveness of Short and Long-term COVID-19 Therapies Inhibiting the Progression of SARS-CoV-2
Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Statera Biopharma, Inc. (NASDAQ: STAB) recently announced that it has officially received Institutional Review Board (IRB) approval to conduct a Phase 1 pilot study at Loma Linda University Health to evaluate STAT-205 as a treatment in the mitigation of SARS-CoV-2 progression. STAT-205 is a breakthrough immuno-modulator designed to decrease elevated inflammatory responses that are associated with viral infections and inhibit viral replication in human lung cells. Its efficacy was successfully demonstrated during preclinical in vitro studies, where STAT-205 was able to inhibit the replication of…
You May Also Like
What is ImQuest, and How is Statera Biopharma using it to Develop New Immune Therapies for Cancer, Infectious Disease and Autoimmune Disorders?
Rowdy Rooster Hemp Unleashed | Official Launch of Generation Hemp’s Animal Bedding Brand for Small Animals
Is Generation Hemp Now A Leader in Pure-Play Hemp Operations for the Industrial Sector?
-
Research Shows that Animals, too, Need a Good Night’s Sleep
Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. There’s a genetic link between narcolepsy, sleeping with one eye open and the so-called “fear conditioning” of so many different animals on this planet. A lack of sleep is not only dangerous to the health of humans but it also puts the health of these animals at risk, no matter their shape, size or species. Social hierarchy, diet, brain size and body mass are contributing factors to how much sleep particular animals naturally need. Outside factors might even include their immediate environment and a…
-
Statera BioPharma: The Ticker Formerly Known as CBLI
Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. On September 1, 2021, Cytocom officially became listed as Statera BioPharma, Inc. (NASDAQ: STAB), as it updated its ticker symbol from CLBI to STAB within the Nasdaq markets. This change in name comes as a natural progression, as the company shifts gears toward placing a more strategic focus on restoring total immune health — including autoimmune and inflammatory diseases, such as fibromyalgia and multiple sclerosis, blood disorders like anemia and lupus, even cancer and various other infectious diseases. The company began trading as CLBI, last month,…
You May Also Like
Lineage, Pioneering a New Branch of Medicine — OpRegen Continues to Show Promising Results in Dry AMD with Geographic Atrophy
Rowdy Rooster Hemp Unleashed | Official Launch of Generation Hemp’s Animal Bedding Brand for Small Animals
What is ImQuest, and How is Statera Biopharma using it to Develop New Immune Therapies for Cancer, Infectious Disease and Autoimmune Disorders?
-
Biotricity Reports Q1 Earnings at 290% for FY2022
Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Biotricity (NASDAQ: BTCY) has been taking the world of medtech by storm, introducing primary care providers across the country to its remote heart monitoring devices. Always connected, these wearable devices have been giving power back to those suffering from chronic cardiac conditions and simultaneous comorbidities — the simultaneous presence of two or more diseases or medical conditions and often relative of one another. Through remote heart monitoring and diagnostic technologies, doctors can screen their patients from a distance, even alerted to a possible emergency if the…
